Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review

INTRODUCTION: Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunkureddi, Prashanth, Latremouille-Viau, Dominick, Meiselbach, Mark K., Xie, Jipan, Hur, Peter, Joshi, Reeti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393268/
https://www.ncbi.nlm.nih.gov/pubmed/30612321
http://dx.doi.org/10.1007/s40744-018-0137-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393268/
https://www.ncbi.nlm.nih.gov/pubmed/30612321
http://dx.doi.org/10.1007/s40744-018-0137-z

Ejemplares similares